Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZBMUF trial: effects of ultrafiltration and high-dose aprotinin on bivalirudin pharmacokinetics during cardiopulmonary bypass
2005-003053-26Phase 3Completed
- Sponsor
- The Medicines Company
- Start
- Dec 2005
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bivalirudin in coronary arteriosclerosis (2 arms), sponsored by The Medicines Company. Primary endpoint: Pharmacokinetic parameters of bivalirudin with and without ZBMUF and high-dose aprotinin. Started Dec 2005; status: completed.
02
Drugs
bivalirudin
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on 2005-003053-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003053-26.